244022-63-7

Basic information

• Product Name: 3,5-DIFLUOROBENZHYDRAZIDE
• Synonyms: BUTTPARK 35\03-76;3,5-DIFLUOROBENZHYDRAZIDE;3,5-DIFLUOROBENZOIC ACID HYDRAZIDE;Albb-007082;3,5-Difluorobenzoicacidhydrazide97%
• CAS NO: 244022-63-7
• Molecular Formula: C₇H₆F₂N₂O
• Molecular Weight: 172.13
• Mol File: 244022-63-7.mol

Chemical Properties

• Melting Point: 168-170°C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.372g/cm³
• Refractive Index: 1.53
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 3,5-DIFLUOROBENZHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIFLUOROBENZHYDRAZIDE(244022-63-7)
• EPA Substance Registry System: 3,5-DIFLUOROBENZHYDRAZIDE(244022-63-7)

Safety Data

• Hazard Codes: Xi
• Statements: 20/21/22
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 244022-63-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3,5-DIFLUOROBENZHYDRAZIDE is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3,5-DIFLUOROBENZHYDRAZIDE is utilized as an intermediate in the production of agrochemicals, which are essential for enhancing crop protection and yield.
Used in Medicinal Chemistry:
3,5-DIFLUOROBENZHYDRAZIDE is used as an antimicrobial agent for its capacity to inhibit the growth of certain bacteria and fungi, thereby playing a role in the discovery and development of new antimicrobial treatments.
Used in Material Science:
3,5-DIFLUOROBENZHYDRAZIDE is used as a precursor in the synthesis of new materials and polymers with unique properties, contributing to advancements in material science and the creation of innovative products with specialized applications.

InChI:InChI=1/C7H6F2N2O/c8-5-1-4(7(12)11-10)2-6(9)3-5/h1-3H,10H2,(H,11,12)

Upstream product

• 455-40-3 3,5-difluorobenzoic acid 
• 129714-97-2 3,5-difluorobenzoyl chloride 

Downstream Products

• 863713-36-4 5-(3,5-difluorophenyl)-4-methyl-2,4-dihydro-3H-1,2,4-triazole-3-thione 
• 1219921-85-3 C₁₂H₁₂F₂N₂O₄ 
• 1310412-53-3 N-(2-butoxyethyl)-3,5-difluorobenzamide 
• 1310412-57-7 N-(2-tert-butoxyethyl)-3,5-difluorobenzamide 
• 1310412-61-3 3,5-difluoro-N-(tetrahydropyran-3-yl)benzamide 
• 1310412-64-6 N-[2-(tert-butyldimethylsilanyloxy)-2-phenylethyl]-3,5-difluorobenzamide 
• 1310412-45-3 1-(3,5-difluorobenzoylamino)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester 
• 863713-25-1 3-(3,5-difluorophenyl)-4-methyl-5-(methylthio)-4H-1,2,4-triazole 
• 863711-80-2 [5-(3,5-difluoro-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-methyl-amine 

Relevant articles and documents

Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine

A pharmacophore model was built, based on known CGRP receptor antagonists, and this was used to aid the identification of novel leads. Analogues were designed, modelled and synthesised which incorporated alternative 'LHS' fragments linked via either an amide or urea to a privileged 'RHS' fragment commonly found in CGRP receptor antagonists. As a result a novel series of oxadiazole CGRP receptor antagonists has been identified and the subsequent optimisation to enhance both potency and bioavailability is presented.

3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS

The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salt thereof: wherein " G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl and indazolyl; " p is an integer ranging from 0 to 5; " R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5, or corresponds to a group R5; " each R2 is independently hydrogen, fluorine or C1-4alkyl; " n is 2, 3, 4, or 5; " R3 is C1-4alkyl; " R4 is hydrogen, or a C1-4alkyl group, a benzyl group, a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5;or R4 is a -SR6 group; " R5 is selected from a group consisting of: isoxazolyl, -CH2-N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl and 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from a group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy and C1-4alkanoyl; " R6 is C1-4alkyl or -CH2C3-4cycloalkyl; and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1. processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or cognition impairment.

Triazole derivatives

The present invention relates to triazole and imidazole derivatives of formula I and to their pharmaceutically acceptable acid addition salts. These compounds are NMDA receptor subtype blockers and are useful for the treatment of diseases related to the NMDA receptor.